Serum IL-17A and IL-6 in paediatric Mycoplasma pneumoniae pneumonia: implications for different endotypes

References

• Tsai TA, Tsai CK, Kuo KC, et al. Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children. J Microbiol Immunol Infect. 2021 Aug;54(4):557–565. doi:10.1016/j.jmii.2020.10.002
   PubMedGoogle Scholar
• Yen MH, Yan DC, Wang CJ, et al. The clinical significance of and the factors associated with macrolide resistance and poor macrolide response in pediatric Mycoplasma pneumoniae infection: a retrospective study. J Microbiol Immunol Infect. 2023 Jun;56(3):634–640. doi:10.1016/j.jmii.2023.01.010
   PubMedGoogle Scholar
• Liu JR, He RX, Zhang XY, et al. Clinical features and “early” corticosteroid treatment outcome of pediatric Mycoplasma pneumoniae pneumonia. Front Cell Infect Microbiol. 2023 Apr 4;13:1135228. doi:10.3389/fcimb.2023.1135228
   PubMed Web of Science ®Google Scholar
• Kawakami N, Namkoong H, Saito F, et al. Epidemiology of macrolide-resistant Mycoplasma pneumoniae by age distribution in Japan. J Infect Chemother. 2021 Jan;27(1):45–48. doi:10.1016/j.jiac.2020.08.006
   PubMed Web of Science ®Google Scholar
• Yang EA, Kang HM, Rhim JW, et al. Early corticosteroid therapy for Mycoplasma pneumoniae pneumonia irrespective of used antibiotics in children. J Clin Med. 2019 May 22;8(5):726. doi:10.3390/jcm8050726
   PubMed Web of Science ®Google Scholar
• Conroy G. What’s behind China’s mysterious wave of childhood pneumonia? Nature. 2023 Nov 27. doi:10.1038/d41586-023-03732-w
   Google Scholar
• Waites KB, Xiao L, Liu Y, et al. Mycoplasma pneumoniae from the respiratory tract and beyond. Clin Microbiol Rev. 2017 Jul;30(3):747–809. doi:10.1128/CMR.00114-16
   PubMed Web of Science ®Google Scholar
• Yang TI, Chang TH, Lu CY, et al. Mycoplasma pneumoniae in pediatric patients: do macrolide-resistance and/or delayed treatment matter? J Microbiol Immunol Infect. 2019 Apr;52(2):329–335. doi:10.1016/j.jmii.2018.09.009
   PubMedGoogle Scholar
• Tanaka H. Correlation between radiological and pathological findings in patients with Mycoplasma pneumoniae pneumonia. Front Microbiol. 2016 May 11;7:695. doi:10.3389/fmicb.2016.00695
   PubMed Web of Science ®Google Scholar
• Miyashita N, Narita M, Tanaka T, et al. Histological findings in severe Mycoplasma pneumoniae pneumonia. J Med Microbiol. 2017 May;66(5):690–692. doi:10.1099/jmm.0.000501
   PubMed Web of Science ®Google Scholar
• Lee YC, Chang CH, Lee WJ, et al. Altered chemokine profile in refractory Mycoplasma pneumoniae pneumonia infected children. J Microbiol Immunol Infect. 2021 Aug;54(4):673–679. doi:10.1016/j.jmii.2020.03.030
   PubMedGoogle Scholar
• Xu XF, Li XJ, Liu JL, et al. Serum cytokine profile contributes to discriminating M. pneumoniae pneumonia in children. Cytokine. 2016 Oct;86:73–78. doi:10.1016/j.cyto.2016.07.018
   PubMed Web of Science ®Google Scholar
• Tong L, Huang SM, Zheng C, et al. Refractory Mycoplasma pneumoniae pneumonia in children: early recognition and management. J Clin Med. 2022 May 17;11(10):2824. doi:10.3390/jcm11102824
   PubMed Web of Science ®Google Scholar
• Tanaka H, Narita M, Teramoto S, et al. Role of interleukin-18 and T-helper type 1 cytokines in the development of Mycoplasma pneumoniae pneumonia in adults. Chest. 2002 May;121(5):1493–1497. doi:10.1378/chest.121.5.1493
   PubMed Web of Science ®Google Scholar
• Masters IB, Isles AF, Grimwood K. Necrotizing pneumonia: an emerging problem in children? Pneumonia (Nathan). 2017 Jul 25;9:11, doi:10.1186/s41479-017-0035-0
   PubMedGoogle Scholar
• Cheng Q, Zhang H, Shang YX, et al. Clinical features and risk factors analysis of bronchitis obliterans due to refractory Mycoplasma pneumoniae pneumonia in children: a nomogram prediction model. BMC Infect Dis. 2021 Oct 21;21(1):1085. doi:10.1186/s12879-021-06783-4
   PubMed Web of Science ®Google Scholar
• Teper A, Colom AJ, Schubert R, et al. Update in postinfectious bronchiolitis obliterans. Pediatr Pulmonol. 2023 Jun 28. doi:10.1002/ppul.26570
   Web of Science ®Google Scholar
• Christenson SA, Smith BM, Bafadhel M, et al. Chronic obstructive pulmonary disease. Lancet. 2022 Jun 11;399(10342):2227–2242. doi:10.1016/S0140-6736(22)00470-6
   PubMed Web of Science ®Google Scholar
• Ritzmann F, Lunding LP, Bals R, et al. IL-17 Cytokines and chronic lung diseases. Cells. 2022 Jul 6;11(14):2132. doi:10.3390/cells11142132
   PubMed Web of Science ®Google Scholar
• Fujisawa T, Chang MM, Velichko S, et al. NF-κB mediates IL-1β- and IL-17A-induced MUC5B expression in airway epithelial cells. Am J Respir Cell Mol Biol. 2011 Aug;45(2):246–252. doi:10.1165/rcmb.2009-0313OC
   PubMed Web of Science ®Google Scholar
• Okuda K, Shaffer KM, Ehre C. Mucins and CFTR: their close relationship. Int J Mol Sci. 2022 Sep 6;23(18):10232. doi:10.3390/ijms231810232
   PubMed Web of Science ®Google Scholar
• Beringer A, Miossec P. Systemic effects of IL-17 in inflammatory arthritis. Nat Rev Rheumatol. 2019 Aug;15(8):491–501. doi:10.1038/s41584-019-0243-5
   PubMed Web of Science ®Google Scholar
• Diaz AA, Orejas JL, Grumley S, et al. Airway-occluding mucus plugs and mortality in patients with chronic obstructive pulmonary disease. JAMA. 2023 Jun 6;329(21):1832–1839. doi:10.1001/jama.2023.2065
   PubMed Web of Science ®Google Scholar
• Kim V, Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013 Feb 1;187(3):228–237. doi:10.1164/rccm.201210-1843CI
   PubMed Web of Science ®Google Scholar
• Liu JR, Shen RF, Feng L, et al. Proteomics study of Mycoplasma pneumoniae pneumonia reveals the Fc fragment of the IgG-binding protein as a serum biomarker and implicates potential therapeutic targets. Front Med. 2022 Jun;16(3):378–388. doi:10.1007/s11684-021-0840-y
   PubMed Web of Science ®Google Scholar
• Pacha O, Sallman MA, Evans SE. COVID-19: a case for inhibiting IL-17? Nat Rev Immunol. 2020 Jun;20(6):345–346. doi:10.1038/s41577-020-0328-z
   PubMed Web of Science ®Google Scholar
• Shibabaw T. Inflammatory cytokine: IL-17A signaling pathway in patients present with COVID-19 and current treatment strategy. J Inflamm Res. 2020 Oct 6;13:673–680. doi:10.2147/JIR.S278335
   PubMed Web of Science ®Google Scholar
• Konieczny P, Xing Y, Sidhu I, et al. Interleukin-17 governs hypoxic adaptation of injured epithelium. Science. 2022 Jul 8;377(6602):eabg9302. doi:10.1126/science.abg9302
   PubMed Web of Science ®Google Scholar
• Bester J, Matshailwe C, Pretorius E. Simultaneous presence of hypercoagulation and increased clot lysis time due to IL-1β, IL-6 and IL-8. Cytokine. 2018 Oct;110:237–242. doi:10.1016/j.cyto.2018.01.007
   PubMed Web of Science ®Google Scholar
• Pongpitakmetha T, Hemachudha P, Rattanawong W, et al. COVID-19 related acute necrotizing encephalopathy with extremely high interleukin-6 and RANBP2 mutation in a patient with recently immunized inactivated virus vaccine and no pulmonary involvement. BMC Infect Dis. 2022 Jul 23;22(1):640. doi:10.1186/s12879-022-07610-0
   PubMed Web of Science ®Google Scholar
• McElvaney OJ, Curley GF, Rose-John S, et al. Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respir Med. 2021 Jun;9(6):643–654. doi:10.1016/S2213-2600(21)00103-X
   PubMed Web of Science ®Google Scholar
• Shochet GE, Brook E, Bardenstein-Wald B, et al. TGF-β pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling. Respir Res. 2020 Feb 18;21(1):56. doi:10.1186/s12931-020-1319-0
   PubMed Web of Science ®Google Scholar
• Kurche JS, Stancil IT, Michalski JE, et al. Dysregulated cell-cell communication characterizes pulmonary fibrosis. Cells. 2022 Oct 21;11(20):3319. doi:10.3390/cells11203319
   PubMed Web of Science ®Google Scholar
• Neveu WA, Allard JB, Dienz O, et al. IL-6 is required for airway mucus production induced by inhaled fungal allergens. J Immunol. 2009 Aug 1;183(3):1732–1738. doi:10.4049/jimmunol.0802923
   PubMed Web of Science ®Google Scholar
• Corlateanu A, Mendez Y, Wang Y, et al. Chronic obstructive pulmonary disease and phenotypes: a state-of-the-art. Pulmonology. 2020 Mar–Apr;26(2):95–100. doi:10.1016/j.pulmoe.2019.10.006
   PubMed Web of Science ®Google Scholar
• Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Eng J Med. 2004 Jun 24;350(26):2645–2653. doi:10.1056/NEJMoa032158
   PubMed Web of Science ®Google Scholar